Studientitel

Status

Seit

Medikation

PROOF 302 Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)

Aktiv

20.10.2020 Rekrutierung aktiv

Infigratinib

Basilea DZB-CS-201 An open-label multi-cohorte Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02)

Aktiv

08.06.2020

MK-3475-866 / KEYNOTE 866 Peri-operative Pembrolizumab + Neoadjuvant Chemotherapv vs Periop. Placebo + Neoadjuvant Chemotherapy in Cisplatin Eligible Patients with Muscle-Invasive Bladder Cancer

Aktiv

19.12.2019 Rekrutierung aktiv

Peri-operative Pembrolizumab + Neoadjuvant Chemotherapv vs Periop. Placebo + Neoadjuvant Chemotherapy

POTOMAC: Phase III Randomized, Open-label, Multi-center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as Combination Therapy versus BCG alone in High Risk, BCG-Naïve Non-muscle-Invasive Bladder Cancer Patients

Aktiv

Rekrutierung abgeschlossen

Durvalumab and BCG vs BCG alone

NKTR-214 Eine randomisierte, nicht vergleichende, unverblindete Studie der Phase 2 zu NKTR-214 in Kombination mit Nivolumab und zu Chemotherapie bei Patienten mit lokal fortgeschrittenem oder metastasierendem Urothelkarzinom mit niedriger PD-L1-Expression, die für eine Cisplatin-Therapie nicht geeignet sind

Aktiv

Rekrutierung abgeschlossen

Incyte - A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Aktiv

Rekrutierung abgeschlossen

Tyrosine Kinase Inhibitor INCB054828

Immunomedics: A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer” Protocol: IMMU-132-13

In Planung

Cabopoint: Ipsen, Protocol number F-FR-60000-023: A Phase II, Multicentre, Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a clear-cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors (Parexel Project No. 243458)

In Planung

SGN22E-003 An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer

In Planung

Ansprechpartner

Sektionsleiterin PD Dr. M. De Santis, OÄ Dr. U. Steiner, A. Biniszkiewicz, Tel.: Tel.: 030-450 615092, Fax: 030-450 7515927